

## Special Issue

# New Therapeutic Approaches, Biomarkers for Diagnosis, Prognosis and Therapy Prediction in Breast Cancer and Breast Cancer Recurrence

### Message from the Guest Editor

Over the last two decades, the tumor recurrence has become a worldwide problem of high scientific and clinical interest. The clinical data show that nearly 30% of breast cancer patients undergo recurrence during follow-up. Despite these efforts, the incidence of breast cancer recurrence is currently increasing because of the ability of breast cancer cells to become resistant to the common therapies, resulting in a strong increase in metastatic capacity. In this Special Issue, we will focus on generating better models of relapse, resulting in a more complete understanding of the metabolic and regulatory mechanisms of drug resistance, the role of the microenvironment in breast cancer, the role of genetic predisposition in the control and prognosis of breast cancer, and other molecular differences that could lead to the development and discovery of new targeted biomarkers and therapeutic approaches that offer a unique opportunity to better define the patterns of late recurrence in breast cancer.

---

### Guest Editor

Dr. Marco Fiorillo

Biomedical Research Centre, University of Salford, Manchester, UK

---

### Deadline for manuscript submissions

closed (30 September 2021)



## Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 5.7  
Indexed in PubMed



[mdpi.com/si/46702](https://mdpi.com/si/46702)

*Journal of Clinical Medicine*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 5.7  
Indexed in PubMed



[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm.mdpi.com)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67000  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1  
(General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.3 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2024).